Telemus Capital LLC Sells 153 Shares of Humana Inc. (NYSE:HUM)

Telemus Capital LLC cut its holdings in Humana Inc. (NYSE:HUM) by 9.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,526 shares of the insurance provider’s stock after selling 153 shares during the period. Telemus Capital LLC’s holdings in Humana were worth $699,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HUM. Ronald Blue Trust Inc. lifted its stake in Humana by 26.8% in the third quarter. Ronald Blue Trust Inc. now owns 189 shares of the insurance provider’s stock valued at $84,000 after purchasing an additional 40 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management lifted its stake in Humana by 7.1% in the third quarter. B & T Capital Management DBA Alpha Capital Management now owns 7,463 shares of the insurance provider’s stock valued at $3,631,000 after purchasing an additional 496 shares during the last quarter. Meridian Wealth Management LLC lifted its stake in Humana by 71.3% in the third quarter. Meridian Wealth Management LLC now owns 6,912 shares of the insurance provider’s stock valued at $3,363,000 after purchasing an additional 2,876 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Humana by 103.0% in the third quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock valued at $1,403,000 after purchasing an additional 1,463 shares during the last quarter. Finally, Caprock Group LLC lifted its stake in Humana by 3.6% in the third quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock valued at $693,000 after purchasing an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Down 0.9 %

Shares of NYSE:HUM opened at $325.30 on Tuesday. The stock’s 50-day moving average price is $330.09 and its 200-day moving average price is $399.70. Humana Inc. has a 12-month low of $299.23 and a 12-month high of $541.21. The stock has a market capitalization of $39.25 billion, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63.

Humana (NYSE:HUM) last announced its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $26.46 billion for the quarter, compared to the consensus estimate of $25.47 billion. During the same period last year, the business posted $1.62 earnings per share. The firm’s quarterly revenue was up 17.9% compared to the same quarter last year. On average, equities analysts anticipate that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. Humana’s dividend payout ratio is currently 17.86%.

Insider Transactions at Humana

In other news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on HUM shares. Deutsche Bank Aktiengesellschaft downgraded Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $595.00 to $360.00 in a research report on Thursday, January 25th. TD Cowen dropped their target price on Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Truist Financial restated a “hold” rating and set a $550.00 target price on shares of Humana in a research report on Friday, January 19th. Wells Fargo & Company lowered their price objective on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Finally, Barclays lowered their price objective on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $454.63.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.